{"filings":[{"id":96681,"accession_number":"0001906324-26-000023","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"QuidelOrtho Q1 net loss $92M; revenue $620M; cuts full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $92M ($1.35 diluted loss per share); adjusted diluted EPS loss $0.04; revenue $620M.","Point of Care revenue $113M (-34% YoY) on weak respiratory season; Labs $353M (-5%); Immunohematology $138M (+8%).","Full-year 2026 guidance cut: revenue $2.70-2.75B (prev. $2.7-2.9B), adj. EBITDA $615-630M (prev. $630-670M), adj. EPS $1.80-2.00 (prev. $2.00-2.42).","Acquired LEX Diagnostics in April for ultra-fast point-of-care molecular diagnostics platform.","U.S. launch of High-Sensitivity Troponin and international rollout of VITROS 450 platform underway."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":619800000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96680,"accession_number":"0001906324-26-000013","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"QuidelOrtho prelim Q1 rev $615-620M; weaker respiratory season, China headwinds","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Prelim Q1 2026 revenue of $615-$620M; U.S. flu-like illness visits down ~30% YoY.","China distributor sales slow on proposed NHSA reimbursement cuts; EMEA orders delayed by Middle East conflict.","Q1 2026 free cash flow guided to negative $(65)-$(70)M; positive full-year still expected.","Low end of FY 2026 guidance remains achievable; full discussion on May 5 earnings call.","Core business (>70% of total rev) remains strong; cost actions underway to drive 2026 performance."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":619800000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110796,"accession_number":"0001193125-26-120684","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"QuidelOrtho appoints Nate Sisitsky as Chief Legal Officer; Michelle Hodges retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michelle Hodges retires as Chief Legal Officer and Corporate Secretary effective March 23, 2026; will serve as special advisor for up to 24 months.","Nathaniel 'Nate' Sisitsky appointed Chief Legal Officer effective March 23, 2026; reports to CEO Brian Blaser.","Sisitsky brings over 25 years of legal experience; most recently Chief Legal Officer at STAAR Surgical."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110795,"accession_number":"0001193125-26-051461","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Joseph M. Busky to retire effective June 30, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph M. Busky notified QuidelOrtho of his retirement on February 9, 2026.","Retirement effective June 30, 2026; no replacement named yet.","Departure is for personal reasons, not related to any disagreement with the company.","Busky served as CFO and principal financial officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110794,"accession_number":"0001906324-26-000003","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"QuidelOrtho reports FY25 revenue $2.73B, adjusted EBITDA $597M; guides FY26 revenue $2.7-2.9B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY25 total revenue $2.73B in line with guidance; Labs revenue +6% as reported, non-respiratory +5% ex Donor Screening.","GAAP net loss $1.13B includes $701M goodwill impairment; adjusted diluted EPS $2.12 (in range $2.00-$2.15).","Adjusted EBITDA margin expanded 240 bps to 22%; adjusted EBITDA $597M (in range $585-$605M).","FY26 guidance: revenue $2.7-2.9B, adjusted EBITDA $630-670M (23.3% margin), free cash flow $120-160M.","Q4 revenue $724M, adjusted EBITDA $153M, adjusted EPS $0.46; Labs +8% as reported."],"consensus_eps_estimate":null,"consensus_eps_actual":-16.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":2730200000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110793,"accession_number":"0001193125-26-039440","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Matthew W. Strobeck to not stand for re-election; Board will reduce to 10","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew W. Strobeck notified Board on Jan 30, 2026 of decision not to stand for re-election at 2026 annual meeting.","He will continue serving as a Board member until the annual meeting, after which Board size reduces from 11 to 10.","Decision was due to other professional commitments and not the result of any disagreement with the Company or management.","Strobeck served on the Board for eight years; Company expressed gratitude for his contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127427,"accession_number":"0001193125-25-273317","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"QuidelOrtho Q3: revenue $700M, adj. EBITDA margin 25%, core growth 5% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $700M; core revenue (ex-COVID/Donor Screening) grew 5% as reported.","Adjusted EBITDA margin improved 180 bps to 25%; full-year guidance maintained at 22%.","Labs +4%, IH +5%, Triage +7% (constant currency); non-respiratory up 6% CC.","Respiratory revenue $112M (-32% YoY); COVID sales down 63%.","Pending LEX Diagnostics acquisition on track; VITROS High Sensitivity Troponin cleared in U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":-14.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":2006600000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127426,"accession_number":"0001906324-25-000158","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"QuidelOrtho Q3 revenue $700M (-4% YoY); GAAP loss $10.78/sh on $701M impairment; Adj EPS $0.80","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $700M, down 4% YoY; non-respiratory revenue up 5% as reported, 6% constant currency ex-Donor Screening.","GAAP net loss $733M includes $701M non-cash goodwill impairment; GAAP diluted EPS loss $10.78; adjusted diluted EPS $0.80.","Adjusted EBITDA $177M, margin 25%, up 180 bps YoY driven by cost-savings initiatives.","FY2025 guidance narrowed: revenue $2.68-$2.74B, adjusted EBITDA $585-$605M, adjusted diluted EPS $2.00-$2.15.","Completed debt refinancing to improve financial flexibility with reduced amortization; terms not detailed."],"consensus_eps_estimate":null,"consensus_eps_actual":-14.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":2006600000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144208,"accession_number":"0001193125-25-185355","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"QuidelOrtho refinances with $1.15B Term Loan A, $1.45B Term Loan B, $700M revolver","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New credit facility includes $1.15B 5-yr Term Loan A, $1.45B 7-yr Term Loan B, $700M revolver, and $100M delayed draw Term Loan A (undrawn).","Proceeds used to repay existing 2022 credit facility; maturities extended to 2030 (Term Loan A/Revolver) and 2032 (Term Loan B).","Initial applicable rate for Term Loan B is 4.00% (SOFR); Term Loan A/Revolver rate is 2.25% (SOFR) initially, with pricing grid based on leverage.","Financial covenants: max leverage ratio 4.50x (first 3 yrs) then 4.25x; min interest coverage 3.00x.","CFO states priority remains debt reduction and net debt leverage improvement; refinancing provides greater flexibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144207,"accession_number":"0001906324-25-000150","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"QuidelOrtho reports Q2 2025 adjusted EPS of $0.12 vs loss of ($0.07); reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $614M (-3.6% YoY); Labs revenue +4% as reported, but respiratory revenue fell 20% to $47M on lower COVID-19 sales.","GAAP net loss $255M ($3.77 loss per share) vs $148M loss prior year; includes $179M restructuring charges, notably $150M Savanna platform discontinuation.","Adjusted EBITDA $107M (17% margin, +330 bps YoY); achieved $100M annualized cost savings from 2024 initiatives.","Reiterates FY2025 guidance: revenue $2.60-$2.81B, adj. EBITDA $575-$615M, adj. diluted EPS $2.07-$2.57.","Announced intent to acquire LEX Diagnostics; initiated major manufacturing site consolidation."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":1306700000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162552,"accession_number":"0001193125-25-127604","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"QuidelOrtho stockholders approve 6.2M share increase for equity plan, reelect 11 directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Second A&R 2018 Equity Incentive Plan, increasing authorized shares by 6.2M and extending term to May 20, 2035.","All 11 director nominees elected; includes B. Blaser, K. Buechler, J. Chiminski, and others.","Advisory vote on executive compensation passed with 53.6M votes for (5.9M against, 17K abstentions).","Ratification of KPMG as independent auditor for 2025 fiscal year approved with 62.7M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162551,"accession_number":"0001906324-25-000055","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"QuidelOrtho Q1 revenue $693M, +5% ex-COVID/Donor; adjusted EPS $0.74 vs $0.44 YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $693M, -3% reported due to lower COVID/Donor; ex-COVID/Donor +5% as reported and +6% constant currency.","GAAP operating margin improved to 5% from (247%); adjusted EBITDA margin 23%, +450 bps driven by cost-savings.","GAAP diluted loss per share $0.19 vs $25.50 loss prior (which included $1.74B goodwill impairment); adjusted EPS $0.74 vs $0.44.","Labs revenue grew 5% as reported (7% constant currency); Donor Screening declined 62% as business winds down.","Full-year 2025 guidance maintained: revenue $2.60-$2.81B, adjusted EBITDA $575-615M, adjusted diluted EPS $2.07-$2.57."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":692800000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180549,"accession_number":"0001906324-25-000037","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"QuidelOrtho appoints KPMG as auditor, dismisses EY; material weaknesses disclosed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee selected KPMG as independent auditor for FY 2025, dismissing EY effective Feb 28, 2025, after competitive process.","EY's audit reports for 2024 and 2023 had no adverse opinion and no disagreements on accounting principles.","EY identified material weaknesses in internal control over financial reporting related to revenue recognition and deferred tax asset realizability.","An interim material weakness in goodwill impairment assessment (Q1 2024) was fully remediated by Q4 2024.","EY agreed with the disclosures; no prior consultations with KPMG on accounting matters occurred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180548,"accession_number":"0001906324-25-000031","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"QuidelOrtho Q4 GAAP loss $2.28/sh; FY2024 rev $2.78B; guides FY25 rev $2.60-$2.81B, adj EBITDA margin 22%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP diluted loss per share $2.28 vs EPS $0.10 prior year; adjusted EPS $0.63 vs $1.17.","Q4 revenue $708M, down 5% YoY; non-respiratory flat; Labs revenue grew 4% ex-COVID and non-core.","Full-year GAAP net loss $2.03B includes $1.82B goodwill impairment; adjusted EBITDA $543M, margin 19.5%.","FY2025 guidance: revenue $2.60-$2.81B, adjusted EBITDA $575-$615M, adjusted diluted EPS $2.07-$2.57.","Company cites cost-savings initiatives targeting incremental margin improvement and 22% adjusted EBITDA margin in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-30.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":2782900000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180547,"accession_number":"0001906324-25-000003","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"QuidelOrtho expects Q4 2024 revenue of $702-707M, above guidance midpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary total revenue $702-707M, in line with prior guidance; non-respiratory $561-563M, respiratory $141-143M.","CEO states 'positive note' and expects top-line above 2024 guidance midpoint; full results due Feb 12, 2025.","Company highlights cost-savings initiatives and leadership realignment during fiscal 2024.","Respiratory revenue ranges reflect lower Q4 demand compared to prior year; Labs segment also in line."],"consensus_eps_estimate":null,"consensus_eps_actual":-30.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":2782900000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197369,"accession_number":"0001906324-24-000069","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"QuidelOrtho appoints John Chiminski and Scott Huennekens as independent directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointments effective December 6, 2024; both qualify as independent under Nasdaq rules.","Chiminski served as CEO of Catalent (CTLT) from 2009-2022; Huennekens was CEO of Volcano Corporation.","Replace James Prutow and Robert Schmidt who resigned Nov 21, 2024 related to Carlyle secondary offering.","Board expands to 11 directors, 10 independent, following a search led by Nominating Committee.","New directors bring MedTech and diagnostics expertise; no family relationships or material transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197368,"accession_number":"0001193125-24-263447","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Carlyle sells 8.26M QuidelOrtho shares at $35.31; two Carlyle directors resign","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Carlyle Partners VI sells 8,260,183 QDEL shares at $35.31/share; company receives no proceeds.","James R. Prutow and Robert R. Schmidt resign from board effective Nov 21, 2024, per stockholder agreement termination.","Principal Stockholders Agreement with Carlyle terminates upon completion of the sale.","Goldman Sachs acts as sole underwriter; offering expected to close Nov 21, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197367,"accession_number":"0001906324-24-000059","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"QuidelOrtho expands CFO Busky's role to include IT oversight; salary raised to $680,000","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Joseph Busky assumes additional oversight of Information Technology function effective Nov 18, 2024.","Base salary increased from $586,328 to $680,000, effective same date, includes 2025 merit increase.","Leadership reorganization under way; no other officer changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197364,"accession_number":"0001906324-24-000058","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K/A","filed_at":"2024-11-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"QuidelOrtho appoints Philip McLellan as COO, approves salary increase to $515K","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Philip McLellan appointed Chief Operations Officer effective November 15, 2024.","Base salary raised from $399,769 to $515,000 effective November 18, 2024.","Increase includes merit adjustment for 2025; Compensation Committee approved terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197366,"accession_number":"0001906324-24-000051","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"QuidelOrtho terminates EVP CCO and EVP COO; appoints Philip McLellan as COO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Terminated Michael S. Iskra (EVP & CCO) and Robert J. Bujarski (EVP & COO), effective Nov 15, 2024.","Appointed Philip McLellan as Chief Operations Officer, effective Nov 15, 2024.","McLellan previously SVP of Operations since Nov 2020; prior Thermo Fisher and Toyota.","He will enter standard Severance/Change in Control and Indemnification agreements.","No family relationships or related-party transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197365,"accession_number":"0001906324-24-000048","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"QuidelOrtho Q3 GAAP net loss $20M ($0.30 EPS); revenue $727M; reinstates 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $727M vs $744M YoY; Labs revenue grew 4% as reported (5% constant currency).","GAAP net loss $20M ($0.30 diluted EPS) vs loss $13M ($0.19) prior year; GAAP operating margin 2%.","Adjusted EBITDA margin 23.5%, up 80 bps; GAAP operating expenses down $13M to $242M.","Company reinstated 2024 financial guidance after withdrawing prior outlook.","Integration-related charges of $37M; new CTO and CHRO appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":-27.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":2075100000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213609,"accession_number":"0001906324-24-000042","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"QuidelOrtho Q2 2024: revenue $637M, GAAP diluted loss ($2.20)/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $637M, down 4% YoY; lower COVID-19 revenue was primary driver.","GAAP diluted loss per share ($2.20) vs ($0.80) prior year; GAAP operating loss ($118M).","Adjusted diluted loss per share ($0.07) vs +$0.26; adjusted EBITDA $90M (14% margin).","Announced $100M annualized cost-savings initiatives to benefit H2 2024 and H1 2025.","Ex-COVID & U.S. Donor Screening, recurring revenue grew 5% constant currency YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-27.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":1348000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232813,"accession_number":"0001906324-24-000034","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"QuidelOrtho stockholders elect all 10 director nominees, approve say-on-pay, ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ten directors elected with 97.5% to 90.9% of votes cast; highest support for Evelyn Dilsaver (95.6%), lowest for Kenneth Widder (90.9%).","Say-on-pay advisory vote approved: 54,888,387 for, 3,194,023 against, 879,159 abstain, plus 4,262,897 broker non-votes.","Ratification of Ernst & Young as fiscal 2024 auditor: 61,334,670 for, 1,022,808 against, 866,988 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232812,"accession_number":"0001906324-24-000030","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"QuidelOrtho Q1 revenue $711M, GAAP loss $25.50/share; suspends 2024 guidance after new CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $711M, down 16% YoY; ex-COVID revenue grew 5% as reported (6% constant currency).","GAAP diluted loss per share $25.50 from $1.74B goodwill impairment; adjusted EPS $0.44 vs $1.80.","Appointed Brian J. Blaser CEO effective May 6; suspended 2024 financial guidance.","Cost reduction headcount cuts expected to deliver ~$100M annualized savings.","Secured credit agreement amendment for additional flexibility through 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-25.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":711000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232811,"accession_number":"0001906324-24-000025","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"QuidelOrtho appoints Brian J. Blaser as CEO effective May 6, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Blaser, ex-Abbott EVP Diagnostic Products, replaces interim CEO Michael Iskra and interim President Robert Bujarski.","He receives $1M base salary, annual target cash bonus of 125% of base, and equity grants totaling $10M.","Board expanded to 11 members; Blaser joins as director effective May 15, 2024.","Interim Office of the CEO dissolved; Iskra and Bujarski return to prior executive roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232810,"accession_number":"0001906324-24-000021","cik":1906324,"company_name":"QuidelOrtho Corp","ticker":"QDEL","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"QuidelOrtho amends credit agreement; leverage ratio covenant adjusted through 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment temporarily raises max leverage to 4.25x for Q3/Q4 2024, then to 4.00x, stepping to 3.75x after June 2025.","Includes clarifying amendments to negative covenants on guarantees, investments, and subsidiary restrictions.","Borrower paid consent fee of 0.075% on aggregate revolving credit and term loan commitments to participating lenders.","Amendment effective April 25, 2024; no events of default exist after giving effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":917850777.0348743,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}